Alexion Fires CEO, CFO in the Midst of Investigation on Improper Sales Practices
Alexion Pharmaceuticals has fired its CEO and CFO as an ongoing investigation into sales practices continues.
Alexion Pharmaceuticals (ALXN) - Get Report fired its CEO and chief financial, as it is in the midst of an internal investigation looking into allegations of improper sales practices connected with its top selling drug Soliris. Soliris sales have totaled $2.2 billion in the first three quarters of the year. Alexion also said its 10-Q filling for the third quarter will now be filed in January. An Alexian Board member, David Brennan, is taking over immediately as interim CEO. He is a former CEO at AstraZeneca (AZN) - Get Report .
